PerkinElmer Launches New Live Cell Capabilities for Operetta® High Content Imaging System
PerkinElmer Launches New Live Cell Capabilities for Operetta®High Content Imaging System
New capabilities provide increased biologically relevant data for improved efficiency in the drug discovery process
WALTHAM, Mass.--(BUSINESS WIRE)-- PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, has announced enhancements for its Operetta® High Content Imaging System, designed to significantly improve the ability of scientists to perform live cell assays with higher throughput, to help foster a better understanding of normal and aberrant cellular behavior.
The latest version of Operetta's software, Harmony 3.5, enables scientists to track individual cells over time for a better understanding of dynamic processes and to generate more accurate prediction models. (Photo: Business Wire)
Scientists conducting research in the areas of cancer, stem cells or infectious diseases will benefit from the Operetta system's new capabilities to analyze the dynamic behavior of cells using advanced live cell, high content imaging. With the new capabilities, users will be able to accurately observe individual cell behavior over time to better understand dynamic processes in order to generate more accurate prediction models, for example how cancer cells migrate during metastasis or how viruses invade cells.
"We are seeing a trend towards researchers using biological assays that are better models of the physiological environment in vivo earlier in the drug discovery process in order to improve the likelihood of a drug succeeding at clinical trial." said Jim Corbett, President, Diagnostics and Life Sciences, PerkinElmer. "With these new live cell imaging capabilities, our customers will have easy access to a wider range of applications than ever before and will be able to generate more biologically relevant data on how cells respond to compounds, helping to reduce false positives later in the drug discovery process."
The Operetta system's new capabilities include brightfield imaging and environmental chamber options, and a new transmitted light digital phase-contrast mode that enables users to image and segment live cells without using fluorescent dyes. This feature reduces toxic effects of nuclear stains that may negatively impact the viability of cells, enabling longer and more predictive live cell studies. Furthermore, it can help to reduce assay costs.
In addition to the live cell imaging capabilities, the upgraded Operetta system is integrated with advanced informatics solutions, such as PerkinElmer's Columbus™ Image Data Storage and Analysis System for high content imaging data, and the TIBCO®Spotfire® software for data analysis and visualization which enables users to easily combine findings across experiments.
Visit www.perkinelmer.com/Operetta for more information
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2.1 billion in 2012, has about 7,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
TIBCO and Spotfire are registered trademarks of TIBCO Software Inc.
Photos/Multimedia Gallery Available:http://www.businesswire.com/multimedia/home/20130724005135/en/
Edelman (On behalf of PerkinElmer, Inc.)
Paul Barren, 404-460-9679
paul.barren@edelman.com
KEYWORDS: United States Europe Asia Pacific North America Massachusetts
INDUSTRY KEYWORDS:
The article PerkinElmer Launches New Live Cell Capabilities for Operetta® High Content Imaging System originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
